乌司他丁联合参麦注射液治疗ALI的疗效研究

Effects of Ulinastatin associate with Shenmai Injection on Patients with Acute Lung Injury

目的观察乌司他丁联合参麦注射液对急性肺损伤的疗效。方法将60例患者随机分为治疗组和对照组,每组30例,两组常规治疗相同。治疗组加乌司他丁、参麦注射液静滴。观察两组患者临床疗效、治疗前后呼吸频率(RR)及血气分析指标,并测定血浆TNF-α及SOD的含量。结果治疗组临床疗效优于对照组;治疗3天后,治疗组患者RR、PaO2、PaO2/FiO2均优于对照组;治疗3天后始,随着治疗时间的延长,两组TNF-α及SOD检测值均呈下降趋势,治疗组的TNF-α较对照组下降更明显,而治疗组SOD的活力明显高于对照组。结论乌司他丁联合参麦注射液治疗ALI患者,有利于抑制炎症因子、氧自由基生成,临床疗效显著。

Objective To observe the effects of ulinastatin associated with Shenmai Injection on patients with acute lung injury. Methods 60 patients were randomly divided into control group （30） and trial group （30）. Both groups received conventional therapy. The trial group received additional ulinastatin associate with Shenmai Injection. Clinical effects, respiratory rate （ RR）, index of blood gas analysis were observed before and after treatment. The changes of TNF-etand SOD were tested at different time. Results Clinical effects in trial group were better than those in control group. After 3 days of treatment, the RR, PaO2 and PaO2/FiO2 in trial group were better than those in control group. With the time of therpy prolonged, TNF-aand SOD showed a downtrend. TNF-cdn trial group decreased more significantly than that in control group ; The activity of SOD in trial group was higher than that in control group. Conclusion Ulinastatin combined with Shenmai Injection had significant clinical effects on treating patients with ALI, and they can inhibit inflammatory factors and oxyradica.